The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009102318A1
公开(公告)日:2009-08-20
The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
[EN] 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE 1,2,3,4-TÉTRAHYDROISOQUINOLÉINE EN TANT QU'ANTAGONISTES ET AGENTS DE DÉGRADATION SÉLECTIFS DES RÉCEPTEURS DES ŒSTROGÈNES
申请人:NOVARTIS AG
公开号:WO2015092634A1
公开(公告)日:2015-06-25
The present invention relates to compounds of formula (I) in which n, R1, R2, R3, R4and R5 are as defined in the claims; capable of being both potent antagonists and degraders of estrogen receptors. Also described is a process for the preparation of compounds of the invention, and the invention further provides pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
Carbocation Catalyzed Bromination of Alkyl Arenes, a Chemoselective
<i>sp</i>
<sup>
<i>3</i>
</sup>
<i>vs. sp</i>
<sup>
<i>2</i>
</sup>
C−H functionalization.
作者:Shengjun Ni、Mahmoud Abd El Aleem Ali Ali El Remaily、Johan Franzén
DOI:10.1002/adsc.201800788
日期:2018.11.5
The versatility of the trityl cation (TrBF4) as a highly efficient Lewis acid organocatalyst is demonstrated in a light induced benzylic brominaion of alkyl‐arenes under mild conditions. The reaction was conducted at ambient temperature under common hood light (55 W fluorescent light) with catalyst loadings down to 2.0 mol% using N‐bromosuccinimide (NBS) as the brominating agent. The protocol is applicable